CTFA suggests some cosmetic drugs should be exempt from order-of-information label regs.
This article was originally published in The Rose Sheet
Executive Summary
CTFA ADVOCATES "SPECIAL" LABEL REGS FOR COSMETIC DRUGS WITHOUT DOSE LIMITS at a Sept. 29 FDA public hearing on OTC drug labeling. Cosmetic, Toiletry, and Fragrance Association Associate General Counsel James Skiles stressed that the association "fully supports" the OTC label reform proposal presented by Nonprescription Drug Manufacturers Association VP-Science and Technology William Soller, PhD, at the hearing. However, he maintained that "cosmetic drugs that do not bear dosage limitations" should be exempt from NDMA's order of information for labels, which stipulates that active ingredients should be listed first.